In the last three months, 15 analysts have published ratings on Intra-Cellular Therapies (NASDAQ:ITCI), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 9 | 2 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 2 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 4 | 0 | 0 | 0 |
| 3M Ago | 2 | 3 | 2 | 0 | 0 |
Analysts have set 12-month price targets for Intra-Cellular Therapies, revealing an average target of $100.93, a high estimate of $130.00, and a low estimate of $74.00. This current average has increased by 2.78% from the previous average price target of $98.20.
Investigating Analyst Ratings: An Elaborate Study
An in-depth analysis of recent...
Login or create a forever free account to read this news
Sign up/Log in
